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Context: The relationship between rising body mass index (BMI) and prospective risk of nonalco-
holic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is virtually absent.
Objective: Determine the extent of the association between BMI and risk of future NAFLD diag-
nosis, stratifying by sex and diabetes.
Design: Two prospective studies using Humedica and Health Improvement Network (THIN) with
1.54 and 4.96 years of follow-up, respectively.
Setting: Electronic health record databases.
Participants: Patients with a recorded BMI measurement between 15 and 60 kg/m2, and smoking
status, and1yearofactive statusbeforebaselineBMI. Patientswithadiagnosisorhistoryof chronic
diseases were excluded.
Interventions: None.
Main Outcome Measure: Recorded diagnosis of NAFLD/NASH during follow-up (Humedica Inter-
national Classification of Diseases, Ninth Revision code 571.8, and read codes for NAFLD andNASH
in THIN).
Results: Hazard ratios (HRs) were calculated across BMI categories using BMI of 20–22.5 kg/m2 as
the reference category, adjusting for age, sex, and smoking status. Risk of recorded NAFLD/NASH
increased linearly with BMI and was approximately 5-fold higher in Humedica (HR  4.78; 95%
confidence interval, 4.17–5.47) and 9-fold higher in THIN (HR  8.93; 7.11–11.23) at a BMI of
30–32.5 kg/m2 rising to around 10-fold higher in Humedica (HR  9.80; 8.49–11.32) and 14-fold
higher in THIN (HR  14.32; 11.04–18.57) in the 37.5- to 40-kg/m2 BMI category. Risk of NAFLD/
NASH was approximately 50% higher in men and approximately double in those with diabetes.
Conclusions: These data quantify the consistent and strong relationships between BMI and pro-
spectively recordeddiagnoses ofNAFLD/NASHandemphasize the importanceofweight reduction
strategies forpreventionandmanagementofNAFLD. (J Clin EndocrinolMetab101: 945–952, 2016)
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Nonalcoholic fatty liver disease (NAFLD) is currentlythe most common form of liver disease and abnor-
mal liver function tests and its prevalence is increasing due
to the rise in obesity (1). Progression of NAFLDmay lead
to nonalcoholic steatohepatitis (NASH), marked by in-
flammation of the liver, and can further progress to fibro-
sis and eventual cirrhosis.Although simpleNAFLD is usu-
ally benign and does not frequently progress to more
advanced stages of liver disease, because of its high prev-
alence it is an increasing public health concern and a lead-
ing cause of cirrhosis (2, 3). The estimated prevalence of
NAFLDandNASH in the general population varies based
on diagnostic method: NAFLD prevalence is estimated to
be between 6.3% and 33% and NASH around 3%–5%
(4). Prevalence of NAFLD among patients with type 2
diabetes has been estimated as high as 69% based on ul-
trasound diagnosis (5). Accurate prevalence of NASH is
more difficult to estimate because liver biopsy is required
and thus systematic screening or prospective study in the
general population is not possible (6). Recorded diagnosis
of NAFLD is currently the only realistic option of attain-
ing detailed data on incident NAFLD in large studies, ac-
cepting many cases of NAFLD will not be picked up due
to lack of systematic screening in any country.
Although there iswide appreciation of the link between
obesity and risk of both NAFLD and NASH, almost ex-
clusively from cross-sectional studies, large prospective
epidemiological studies linking obesity to incident
NAFLD/NASH are limited, save a recent study in Chinese
subjects in a 5-year follow-up of 5562 normal weight sub-
jects (7), andprevious evidence linkingobesitywith higher
risk for incident cirrhosis (8). Such studies are important
scientifically for clinical management strategies and for
public health information. For example, previously re-
ported data from large prospective studies suggest body
mass index (BMI) more than or equal to 35 kg/m2 is as-
sociated with an approximately 40- to 90-fold increased
diabetes risk compared with reference groups with BMI
less than 22–23 kg/m2 (9, 10). This provides benchmarks
for clinical management and public health guidance be-
yondcross-sectional data, andas such these latter 2 studies
arewidely cited.Onewould anticipate that the association
between BMI and incident NAFLD/NASH is likewise
strong though the prospective evidence is limited.Obesity,
type 2 diabetes, and insulin resistance are closely linked to
NAFLD (11) and weight loss and increased physical ac-
tivity are associated with reductions in liver fat (12, 13).
In this study, using large prospective routinely collected
data (comprising 2.1 million people), we report the re-
lationship betweenBMIand risk of a “recorded”NAFLD/
NASH diagnosis using 2 large electronic health record
(EHR) databases, additionally stratifying by diabetes sta-
tus and sex, to explore issues potentially informative to
future clinical guidelines on management of these condi-
tions. Of course, many patients with NAFLD are not
picked up in the real world due to a variety of reasons and,
as such, our study also provides a useful estimate of NA-
FLD recording in real clinical practice.
Materials and Methods
Databases and analytical sample ascertainment
This study was performed using EHR data from 2 large da-
tabases: The Health Improvement Network (THIN) database
and Humedica EHR database. THIN is a United Kingdom pri-
mary care EHR data resource, including more than 12 million
total patients, of whommore than 3million are current patients.
Patient data inTHINare collected fromUnitedKingdomgeneral
practitioners (GPs) and represent approximately 6%of the total
United Kingdom population. During each consultation between
the GP/nurse and patient, all conditions and symptoms are re-
corded electronically using the Read Clinical Classification ver-
sion 2. Participants are representative of the United Kingdom
population by age, gender, and medical conditions (14). THIN
data were acquired from Cegedim Strategic Data Medical Re-
search (United Kingdom) which licenses the record-level anony-
mized data collected from the National Health Service for use in
medical research. The analyses described herein included current
and past patients with records available in the years of 2003–
2013. The Humedica EHR database contains information on
approximately 25 million patients, 7 million of whom have in-
tegrated outpatient and hospital records.Medical conditions are
recorded using International Classification of Diseases, Ninth
Revision (ICD-9) codes. Our analysis used data from GPs, spe-
cialty care and hospitalizations in the years of 2007–2013. Our
prospective analyses were limited to patients with a recorded
BMI measurement between 15 and 60 kg/m2, and between the
ages of 20 and 85 years for Humedica and ages 20 and 90 years
for THIN. Patients without any recorded BMI measurement or
without recorded smoking status were excluded. One year of
active patient status was required before baseline BMI informa-
tion in an effort to ensure disease history was captured. Patients
with a diagnosis or history of chronic disease (including cardio-
vascular disease, neurodegenerative disease, chronic respiratory
disease, neoplastic disease, or fatty liver disease) before baseline
BMI date were excluded from analysis in an effort to reduce the
impact of chronicdiseases commonly associatedwithweight loss
or non-BMI based risk on our endpoint of interest. Lack of re-
liable information about patient alcohol intake prevented the
specific exclusion of patients with a history of alcohol abuse that
may have been inaccurately diagnosed with NAFLD/NASH.
However, the coding of NAFLD/NASH diagnosis implies that
potential excessive alcohol intake was considered, and rejected,
as a cause of liver disease at the time the diagnosis was recorded.
The final analytical sample anddetails on the inclusion/exclusion
criteria for patients in our sample are described in Figure 1 and
the supplemental data below.
Endpoints
The outcome endpoint for analysis was a recorded diagnosis
of NAFLD or NASH (see Supplemental Table 1). In Humedica,
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the outcome endpoint was determined by the ICD-9 code 571.8
which is specific for nonalcoholic liver disease and includes both
NAFLD and NASH. In THIN, the outcome endpoint was de-
termined using a combination of Read codes for NAFLD and
NASH.Diabetes category in the analytical samplewas defined as
a patient receiving a diabetes diagnosis (either type 1 or type 2)
where thediagnosis occurredanytime earlier than1year after the
baseline BMI date and before the diagnosis of NAFLD/NASH.
Diabetes status was determined in Humedica by the ICD-9 code
250.xx, and in THIN by the read codes C10EXXX and
C10FXXX. The vast majority of cases (90%) of diabetes are
likely to be type 2 diabetes.
Statistical analysis
Cox proportional hazards ratios and 95% confidence inter-
vals for the recording of a diagnosis of NAFLD/NASH were
calculated across BMI categories in patients in the analytical
sample. Patients were grouped in 10 BMI categories at baseline
ranging between 15 and 60 kg/m2. BMI category 20 to less than
22.5 kg/m2 was selected as the reference category. The propor-
tional hazards assumptions for all BMI categories in all per-
formedmodels were tested and confirmed. The statistical model
was adjusted for age (continuous variable), sex (male or female),
and smoking status (categorical variable for never smoker, for-
mer smoker, and current smoker). The analysis was conducted
using all patients meeting the inclusion criteria and it was then
repeated after stratifying patients based on diabetes status and
sex, respectively. Stratified analyses allowed for an interaction
term between diabetes or sex and the BMI categories.
In order to assess potential bias we compared the BMI dis-
tribution of the analytical sample in each database with the pub-
lished BMI distribution for each country. All statistical analyses
were conducted using R version 3.1.2.
Results
Patient characteristics
More than 50% of patients in each database had a
recorded measurement of BMI (Figure 1). Patient charac-
teristics for the analytical sample are provided in Table 1
and Supplemental Figure 1. Age, sex, smoking status and
prevalence of diabetes were broadly similar between the 2
databases. The median follow-up time in the analytical
Figure 1. Patient analytical sample for THIN (A) and Humedica (B).
Table 1. Patient Characteristics in the Analytical Sample for Humedica (2007–2013) and THIN (2003–2013)
Characteristic
Humedica
n  1 048 934
THIN
n  1 133 525
Age (y) 41.8  15.0 42.9  14.8
Sex (%)
Male 390 916 (37.3) 467 540 (41.3)
Female 658 018 (62.7) 665 985 (58.8)
Smoking status (%)
Current smoker 350 622 (33.4) 251 410 (22.2)
Former smoker 237 605 (22.7) 318 425 (28.1)
Never smoker 460 707 (43.9) 563 690 (49.7)
BMI (kg/m2) 28.14  6.43 26.81  5.57
Follow-up time (y) 1.54 (0.70–2.48) 4.96 (2.26–7.55)
Diabetes category in analytical sample (%)
Yes 50 104 (4.8) 45 582 (4.0)
No 998 830 (95.2) 1 087 943 (96.0)
Diagnosis of NASH/NAFLD after baseline 8342 (0.79%) 2989 (0.26%)
Data are presented as mean  SD, median (interquartile range), or n (%).
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sample was longer in THIN compared with Humedica
(4.96 [interquartile range 2.26–7.55] vs 1.54 [interquar-
tile range 0.7–2.48] y). Average BMI (SD) was higher in
Humedica than THIN (28.14  6.43 vs 26.81  5.57
kg/m2).During the study, 8342NAFLD/NASHcaseswere
recorded in Humedica and 2989 in THIN. In the latter
cohort, around only approximately 5% had incident
NASH (precluding meaningful stratified analyses), and
the remainder had incident NAFLD.
Relationship between BMI and NAFLD or NASH
diagnosis
Risk of a recorded NAFLD/NASH diagnosis increased
approximately linearly with increasing BMI in both the
Humedica andTHINpatient databases from the reference
BMI category (20 to 22.5 kg/m2) through to BMI cate-
gory37.5 to less than40kg/m2 (Figure2).RiskofNAFLD/
NASH diagnosis was approximately 9-fold higher in
THIN (hazard ratio [HR] 8.93; 95% confidence inter-
val (CI), 7.11–11.23) and 5-fold higher in Humedica
(4.78; 4.17–5.47) at a BMI of 30–32.5 kg/m2 (Figure 2).
These risks continued to rise to around 14-fold higher in
THIN (HR 14.32; 11.04–18.57) and 10-fold higher in
Humedica (HR  9.80; 8.49–11.32) in the 37.5- to 40-
kg/m2 BMI category compared with the reference cate-
gory. In THIN, the HR per one unit increment BMI was
1.16 (95% CI, 1.16–1.17) and in Humedica it was 1.14
(95% CI, 1.14–1.15).
Sex-stratified analysis
In the sex-stratified analysis (Figure 3),menhad greater
risk of NAFLD/NASH diagnosis compared with women
at every BMI category. The BMI-adjusted HR for men
comparedwithwomenwas 1.58 in THIN (CI, 1.47–1.70)
and 1.40 in Humedica (CI, 1.34–1.46). Furthermore, the
relative risk of men vs women increased with increasing
BMI, although this interaction tested as a linear effect
across categories was significant only for Humedica (P
.0159).
Relationship between BMI and NAFLD/NASH in
patients with or without diabetes
In the analysis stratified by diabetes status, when pa-
tients were compared with the diabetes status-specific ref-
erence BMI category, we observed a greater association of
increasing BMI on NAFLD/NASH diagnosis in patients
without diabetes compared with diabetes patients (Figure
4, A andC). InHumedica, patientswithout diabetes in the
highest BMI category had a HR of more than 10 (HR 
10.55; 9.12–12.20) (Supplemental Table 2) compared
with the reference category, whereas in patients with di-
abetes the HR was approximately 4 (HR  3.67; 2.51–
5.36). Results in THINwere broadly similar (Supplemen-
tal Table 3), and in both cases interaction terms were
significant (P  .00001). When patients with diabetes
were compared with those without diabetes as the refer-
ence categorywith similarBMI, diabetes patients hadHRs
that were near double those without diabetes for all BMI
categories (above 27.5 kg/m2), whereas in the lower BMI
categories the risk of NAFLD/NASH associated with di-
abetes was generally higher at around 3- to 5-fold (Figure
4, B and D). This finding was consistent in both the Hu-
medica and THIN databases such that patients with dia-
betes in thehighestBMIcategory (40–60kg/m2)hadaHR
more than 20 (HR  21.63, 18.26–25.61 [Humedica];
HR  24.88, 16.65–37.19 [THIN]) compared with pa-
tients without diabetes in the reference BMI category.
Overall, the risk of NAFLD/NASH diagnosis was 2-fold
higher in patients with T2D comparedwith those without
T2D after adjusting for BMI (THIN HR  1.96, 1.75–
2.20; Humedica HR  2.30, 2.17–2.44).
Figure 2. HRs for diagnosis of NAFLD or NASH based on BMI category in Humedica (A) and THIN (B). HRs with 95% CI are presented compared
with the reference BMI category of 20 to less than 22.5 kg/m2.
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Evaluating the generalizability of our results
The BMI in our analytical samples was broadly similar
to published data during similar time periods in theUnited
Kingdom (Health Survey for England 2012) (15) and
United States (NHANES 2011–2012) (Supplemental Fig-
ure 2) (16).
Discussion
This study provides 2 important findings. Firstly, that ir-
respective of limited identification of NAFLD in the real
world, the prospective risk for being recorded as having a
diagnosis of NAFLD/NASH increased linearly with in-
Figure 4. HRs for diagnosis of NAFLD or NASH based on BMI category stratified by diabetes status in Humedica (A and B) and THIN (C and D).
HRs with 95% CI are presented compared with the reference BMI category of 20 to less than 22.5 kg/m2. In plots A and C, HRs are based on the
reference BMI category within that group. In plots B and D, HRs are based on the nondiabetic reference BMI category.
Figure 3. HRs for diagnosis of NAFLD or NASH based on BMI category stratified by sex in Humedica (A) and THIN (B). HRs with 95% CI are
presented compared with the reference BMI category of 20 to less than 22.5 kg/m2 in females.
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creasing BMI such that risk of NAFLD/NASH diagnosis
was approximately 5- to 9-fold higher at BMI of 30–32.5
kg/m2 rising to rise toaround10- to14-foldhigher atBMIs
of 37.5–40 kg/m2 compared with patients with BMI 20–
22.5 kg/m2. Second, in both databases the baseline prev-
alence of NAFLD/NASH was a fraction of the estimated
population prevalence in previous studies which em-
ployed systematic hepatic imaging (17, 18). This finding is
expected and suggests that NAFLD is either being missed
or is not looked for in many patients in the real world.
Despite differences in clinical practice in the United
Kingdom compared with the United States, and just over
a 1 kg/m2 difference in average baseline BMI as well as the
difference in follow-up, relative risks of NAFLD/NASH
diagnosis by BMI in both EHR databases were broadly
similar. We also showed that relative increases in risk for
recorded NAFLD/NASH diagnosis according to BMI
were greater in individuals without diabetes compared
with those with diabetes; not unexpected because many
diabetes patients are likely to have NAFLD at diagnosis,
even those at lower BMI. However, absolute risks were
substantially higher in diabetes patients for any given
BMI, a finding which supports the strong pathophysio-
logical link (via ectopic fat) between NAFLD and type 2
diabetes (11). Indeed, it appears as if the association of
diabetes with NAFLD/NASH risk is equivalent to an ap-
proximately 5- to 10-kg/m2 increase in BMI in the non-
diabetes curve; ie, the curve is shifted substantially to the
right. This is particularly evident in the HR for diabetes
patients in the healthy BMI range (20–25 kg/m2) where
the risk of recordedNAFLD/NASHwasmore than 5-fold
compared with patients without diabetes.
These novel findings concur with expectations
grounded almost predominantly in cross-sectional obser-
vations that ectopic liver fat is common in diabetes indi-
viduals at diagnosis (11, 19), but our findings also extend
such observations by providing more granular data. Men
had a modestly greater absolute risk of developing NA-
FLD/NASH inall BMI categories thanwomen, datawhich
fitwithgreater liver fat content inmenand theirhigher risk
of type 2 diabetes atmost BMIs (20). Given the strength of
the findings (in particular very high HRs at elevated
BMIs), the size of the study, its prospective design, and its
contextual consistency with other work, as discussed fur-
ther below, our results are potentially valuable; physicians
need to be aware of the strong and near linear relationship
betweenBMIandNAFLDrisk, and clinicians can relate to
patients that weight is the most important risk factor for
development of NAFLD.
We fully recognize that because fatty liver disease is
often undiagnosed due to the lack of systematic screening,
the relationship between BMI and a recorded diagnosis of
NAFLD/NASHpresented here does not necessarily reflect
the true relationship. In both databases, the baseline prev-
alence was a fraction of the estimated population preva-
lence in previous studieswhich has employed imaging (17,
18). This discrepancy is likely due to the substantial un-
derdiagnosis ofNAFLD; routine screening procedures are
not recommended in any country, andmany patients with
NAFLDarenot recognizedashaving it, because liver func-
tion tests can be normal and even minor elevations are
often not further investigated by imaging. Future studies
are needed to determine whether there is a temporal
change in the recording of NAFLD diagnosis. We believe
there will be as general physicians become more familiar
with the relevant diagnostic algorithms.
Our results may reflect an underestimation of relative
risks if more cases are being missed in overweight/obese
individuals (where cross-sectional imaging studies show
NAFLD to bemuchmore common) or alternatively, there
could be an overestimation of relative risks if a diagnosis
of NAFLD is less likely to be sought in those with lower
BMI.However, critically, several factors lead us to believe
our results from these prospective analyses are reasonably
robust and externally valid. Firstly, cross-sectional studies
using imaging in adults and children report odds ratio
(OR) forNAFLD by higher BMIwhich are in line with, or
sometimes greater than, what we have shown for BMI vs
incident NAFLD/NASH. For example, in the Third Na-
tionalHealth andNutritionExamination Survey,NAFLD
prevalence ascertained by ultrasound was approximately
around 4- to 8-fold higher in the obese as compared with
normal weight individuals in different ethnicities, being
greater in men than women, and greater in diabetes pa-
tients (21). Further, in our recent cross-sectional study of
1874 young males and females (mean age 17.9 y), the
prevalence of fatty liver, ascertained by ultrasound in a
careful and detailedmanner, was 0.4% (5 of 1226), 4.3%
(12 of 279), and 22.2% (26 of 117) for individuals who
werenormal, overweight, andobese, respectively, ie,more
than a 50-fold risk in the obese (22). Secondly, the strong
concordance between results from United States-based
and United Kingdom-based EHR databases, countries
with different obesity rates and health care practices, in-
creases our confidence in the conclusions. Thirdly, one
prospective study in a Chinese population which repeated
ultrasound yearly over 5 years in over 5500 subjects with
around 500 incident NAFLD cases, noted a 13-fold dif-
ference in incidence risk comparing extreme fifths of BMI
(1.53% vs 19.96%), even though the study was limited
entirely to normalweight participants; notably theHRper
1-U BMI in this Chinese study at 1.22 was slightly greater
than what we observed at 1.14 and 1.16 in the 2 EHRs in
adjusted analyses (7). Thus, if anything, our findings of
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HRs in the present 2 EHRs ranging from 5- to 9-fold
higher risks in obese (BMI of 30–32.5 kg/m2) to 10- to
14-fold in superobese (BMIof 37.5–40kg/m2) individuals
relative to lean individuals (20–22.5 kg/m2) appear con-
sistent with cross-sectional findings, and if anything may
potentially underestimate, rather than overestimate, risks.
Fourthly, finding of HRs above 10 for NAFLD/NASH at
higher levels of BMI also supports the associations likely
being causal because such high HRs are unlikely to be
simply due to bias or confounding (bias and confounding
often obscure much weaker associations, ie, where HRs
are2- to 3-fold). Fifthly, higher risks of NAFLD/NASH
in diabetes patients and inmen are externally valid as they
concord with cross-sectional imaging data, as described
herein. Finally, we know modest weight loss (5%) can
lead to reductions in NAFLD (23), whereas more major
weight loss (10%–15%) can substantially reduce NA-
FLD prevalence as demonstrated over a decade ago in a
small series of diabetes patients (24), but an observation
repeated many times since then, again in accordance with
substantial HRs of risk at higher BMI levels.
Strengths and limitations of this work require careful
consideration. The use of EHRs allowed us to access data
from millions of patients, enabling us to study the rela-
tionship between BMI and NAFLD/NASH diagnosis in
keypatient subgroupsand, critically, inamuchmoregran-
ular fashion than previously attempted. Of course, an
ideal study would measure liver fat levels (and all con-
founders) by imaging methods and then repeat these tests
serially over time as incident cases appear. However, such
a study, conducted in the numbers required to adequately
answer the question, does not exist as far as we know in a
wide enough population to be generalizable. A further
strength lies in our approach to limit sample bias through
the exclusion of patients with chronic diseases linked to
weight loss and adjusting for smoking status, both of
which could confound the relationship between BMI and
risk of NAFLD or NASH. Despite the benefits related to
cost, timing, and access to large datasets, limited fol-
low-up time and incomplete patient data represent 2 im-
portant limitations that can lead to bias. For example, in
Humedica, patients without a recorded measurement of
BMI had lower disease prevalence (data available on re-
quest). However, patients without BMI recorded are also
likely to be thinner (thus health care workers do not con-
sider its measurement to be relevant) and at lower risk for
complications. The relative low age of our cohort is per-
haps a notable advantage given the lower potential for
chronic diseases and thus less chance of bias. We did not
have access to alcohol intake data to exclude cases of fatty
liver disease that may have been inaccurately diagnosed.
However, focusing on the NAFLD/NASH diagnosis
should limit the impact of these patients in the results and
implies that potential alcohol intake was considered, and
rejected, as the main cause of liver disease at the time the
diagnosis was recorded by a physician. Moreover, a very
recent cross-sectional study (25) which used similar as-
certainment methods for NAFLD to ours (ie, ICD coding)
reportedORs, adjusted for alcohol intake, broadly similar
to HRs we report in our manuscript (obese vs normal
weightOR9.59).Hence, alcohol intake is unlikely to be
a major bias in our study. We also recognize that future
studies are needed to separately link BMI to incident
NASHalone; we did not have sufficient power in the pres-
ent cohorts to enable suchanalyses. Finally, thepercentage
of overweight and obese patients in our analytical sample
is not dissimilar to published obesity rates for the United
States and United Kingdom during a similar time period
(15, 16), giving our results some external consistency.
In summary, using 2 distinct EHR databases compris-
ing more than 2.1 million people and more than 11 000
incident cases, we have shown 2 things. Firstly, that a
strong and striking near linear relationship exists between
BMI and future risk of recorded NAFLD/NASH, with
higher absolute risks in men and patients with diabetes.
Second, that NAFLD recording rates are far lower than
would be expected from imaging studies, reflecting ab-
sence of systematic screening (currently not advocated)
and relatively modest recognition of NAFLD. Neverthe-
less, as discussed the BMI-NAFLD relationship has strong
external validity. The magnitude and consistency of the
associations, namely a 5- to 10-fold increased risk in the
obese and 10- to 14-fold risk in the morbidly obese high-
lights the importance of both prevention of weight gain
and weight reduction strategies in the prevention and
management of NAFLD.
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